John Overdeck Two Sigma Investments
John Overdeck is a co-founder of Two Sigma Investments, one of the world’s leading quantitative and technology-driven investment firms. Two Sigma applies data science, machine learning, and large-scale computing to markets across asset classes. Overdeck’s firm is a central reference point in discussions of modern systematic investing.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$244M |
| 2 |
Pfizer
PFE
|
+$234M |
| 3 |
Nike
NKE
|
+$201M |
| 4 |
Tesla
TSLA
|
+$200M |
| 5 |
S&P Global
SPGI
|
+$196M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$305M |
| 2 |
Advanced Micro Devices
AMD
|
+$241M |
| 3 |
Invesco QQQ Trust
QQQ
|
+$231M |
| 4 |
Merck
MRK
|
+$199M |
| 5 |
State Street Technology Select Sector SPDR ETF
XLK
|
+$190M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 15.1% |
| 2 | Healthcare | 11.63% |
| 3 | Consumer Discretionary | 11.09% |
| 4 | Financials | 10.76% |
| 5 | Industrials | 9.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2526
Nathan's Famous
NATH
$401M
| $296K | ﹤0.01% |
4,186
-800
| -16% | -$56K |
|
2527
Cass Information Systems
CASS
$734M
| $296K | ﹤0.01% |
6,137
-3,223
| -34% | -$146K |
|
2528
Spok Holdings
SPOK
$221M
| $292K | ﹤0.01% |
18,287
-124,841
| -87% | -$2.05M |
|
2529
VSE Corp
VSEC
$6.11B
| $292K | ﹤0.01% |
3,644
-26,492
| -88% | -$1.81M |
|
|
MOFG
2530
DELISTED
MidWestOne Financial Group
MOFG
| $291K | ﹤0.01% |
12,433
-1,232
| -9% | -$29.6K |
|
|
LOGC
2531
DELISTED
ContextLogic
LOGC
| $291K | ﹤0.01% |
51,062
-221,233
| -81% | -$1.22M |
|
2532
DaVita
DVA
$11.3B
| $290K | ﹤0.01% |
2,101
-50,753
| -96% | -$6.09M |
|
2533
Simply Good Foods
SMPL
$969M
| $289K | ﹤0.01% |
+8,503
| New | +$313K |
|
2534
Belden
BDC
$4.57B
| $288K | ﹤0.01% |
3,112
-2,788
| -47% | -$227K |
|
2535
Molina Healthcare
MOH
$10.4B
| $288K | ﹤0.01% |
700
| – | – |
|
2536
Prelude Therapeutics
PRLD
$526M
| $287K | ﹤0.01% |
60,597
+2,313
| +4% | +$9K |
|
2537
Xeris Biopharma Holdings
XERS
$1.59B
| $287K | ﹤0.01% |
129,864
+32,515
| +33% | +$84.1K |
|
2538
FS Bancorp
FSBW
$336M
| $287K | ﹤0.01% |
8,265
-1,017
| -11% | -$34.9K |
|
|
ATXS
2539
DELISTED
Astria Therapeutics
ATXS
| $286K | ﹤0.01% |
20,291
-13,756
| -40% | -$171K |
|
2540
Lincoln Educational Services
LINC
$806M
| $284K | ﹤0.01% |
27,532
-3,714
| -12% | -$36.2K |
|
2541
Sylvamo
SLVM
$1.47B
| $284K | ﹤0.01% |
4,600
-39,720
| -90% | -$2.12M |
|
2542
SiriusPoint
SPNT
$2.78B
| $283K | ﹤0.01% |
22,271
-28,800
| -56% | -$343K |
|
2543
Avient
AVNT
$4.09B
| $282K | ﹤0.01% |
6,507
-50,692
| -89% | -$1.98M |
|
2544
Inovio Pharmaceuticals
INO
$133M
| $281K | ﹤0.01% |
20,261
-7,163
| -26% | -$61.8K |
|
2545
First Business Financial Services
FBIZ
$586M
| $281K | ﹤0.01% |
7,499
+1,100
| +17% | +$39.6K |
|
2546
State Street SPDR S&P Homebuilders ETF
XHB
$1.41B
| $281K | ﹤0.01% |
2,520
-490
| -16% | -$49K |
|
2547
Compass Therapeutics
CMPX
$456M
| $280K | ﹤0.01% |
141,642
-51,058
| -26% | -$88.2K |
|
2548
BOK Financial
BOKF
$8.42B
| $279K | ﹤0.01% |
+3,036
| New | +$257K |
|
2549
Quanterix
QTRX
$132M
| $279K | ﹤0.01% |
11,837
-67,679
| -85% | -$1.68M |
|
2550
Boston Omaha
BOC
$424M
| $279K | ﹤0.01% |
18,033
-34,899
| -66% | -$549K |
|
Similar funds
John Overdeck's Q1 2024 Portfolio in Review
As of Q1 2024, John Overdeck held 3,518 positions worth $42.6B, down 2.1% from $43.5B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
John Overdeck withdrew a net $4.42B in Q1 2024, closing 532 positions and reducing 1,392 holdings. Its most notable exit was Rivian, an estimated $158M position sold in full.
By sector, the portfolio is most concentrated in Technology at 15% of assets, down from 18% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, John Overdeck opened a new position in Pfizer worth $234M.
- John Overdeck's largest Q1 2024 buy was Pfizer: 8,419,014 shares worth $234M.
- John Overdeck added most to Gilead Sciences in Q1 2024, an estimated $244M increase.
- John Overdeck's biggest Q1 2024 reduction was NVIDIA, cutting an estimated $305M.
- John Overdeck fully exited Rivian in Q1 2024, selling an estimated $158M.
- John Overdeck's ten largest holdings make up 9% of its $42.6B portfolio in Q1 2024.
- John Overdeck opened 408 new positions and closed 532 in Q1 2024.
- John Overdeck's portfolio value fell 2.1% quarter-over-quarter to $42.6B.
Based on Two Sigma Investments's 13F filing for Q1 2024, filed 15 May 2024.